C12N 2770/20023
Virus like particles [vlp]
Official title: Virus like particles [VLP]
C12N2770/20023 (Virus like particles [vlp]) appears on 22 US grants and 83 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 83
- Assignees
- 56
- Inventors
- 213
- Latest grant
- 7 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2004 | 0 | 1 |
| 2005 | 0 | 4 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 1 | 2 |
| 2014 | 0 | 0 |
| 2015 | 2 | 2 |
| 2016 | 1 | 0 |
| 2017 | 1 | 2 |
| 2018 | 2 | 0 |
| 2019 | 0 | 1 |
| 2020 | 1 | 2 |
| 2021 | 0 | 3 |
| 2022 | 4 | 12 |
| 2023 | 1 | 18 |
| 2024 | 4 | 16 |
| 2025 | 2 | 8 |
| 2026 | 2 | 7 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus-like particles7 Apr 2026US 12,594,329 B2University of Denver
- Particles, DNA and RNA27 Jan 2026US 12,533,406 B2Novoscope IP Limited
- Coronavirus vaccine and methods of use thereof2 Sep 2025US 12,403,190 B2
- Replication-competent attenuated chimeric VSV vectors encoding immunogenic SARS-CoV-2 spike proteins27 May 2025US 12,311,021 B2International AIDS Vaccine Initiative
- Virus like nanoparticle compositions and methods thereof3 Dec 2024US 12,156,908 B2New York Blood Center, Inc.
- Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof1 Oct 2026US 2026/0295033 A1
- Switchable mrna expression platform6 Aug 2026US 2026/0224679 A1
- System and method for screening rna aptamer23 Jul 2026US 2026/0209750 A1CRISmers Biotechnologies (Shenzhen) Co., Ltd.
- Method for preparing corona virus-like particles and vaccine comprising the same16 Jul 2026US 2026/0201414 A1National Defense Medical University
- Method for constructing circular rna and vaccine against fipv21 May 2026US 2026/0137770 A1Beijing Syngentech Co., Ltd.
Most cited
By later US patents
- Avian influenza chimeric VLPS18US 8,551,756 B2Novavax, Inc. · 2013
- Mouse-adapted SARS-CoV-2 viruses and methods of use thereof12US 11,225,508 B1The University of North Carolina at Chapel Hill · 2022
- Highly efficient influenza matrix (M1) proteins12US 8,992,939 B2Novavax, Inc. · 2015
- Highly efficient influenza matrix (M1) proteins8US 9,464,276 B2Novavax, Inc. · 2016
- Modified S1 subunit of the coronavirus spike protein2US 11,999,766 B2Boehringer Ingelheim Vetmedia GmbH · 2024